Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease

Haematologica

Volumn 88, Issue 10, 2003, Pages 1169-1175

  Pinton, Piergiacomo Calzavara ^a   Porta, Fulvio ^a   Izzi, Teodosio ^a   Venturini, Marina ^a   Capezzera, Rossana ^a   Zane, Cristina ^a   Notarangelo, Luigi Daniele ^a  

^a Spedali Civili ^*

Author keywords

Graft versus host disease; Phototherapy; Scleroderma; Ultraviolet radiation

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MERCAPTOPURINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE NECROSIS; CHILD; CHRONIC KIDNEY FAILURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; GASTRITIS; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MALIGNANT HISTIOCYTOSIS; PHOTOTHERAPY; REFRACTORY ANEMIA; SCLERODERMA; SIDE EFFECT; ULTRAVIOLET A RADIATION; ULTRAVIOLET IRRADIATION; WISKOTT ALDRICH SYNDROME;

ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PUVA THERAPY; SCLERODERMA, LOCALIZED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0242267559     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100:406-14.
2. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogenic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981;11:1-8.
3. Marcellus DC, Altomonte VL, Farmer ER, Horner TD, Freemer CS, Grant J, et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 1999; 93:66-70.
4. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
5. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72:546-54.
6. Kanamaru A, Takemoto Y, Kakishita E, Dohy H, Kodera Y, Moriyama, et al. FK 506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Bone Marrow Transplant 1995;15:885-9.
7. Mookerjee B, Altomonte V, Vogelsand G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999;24:517-20.
8. Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky R, Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant 1998;22: 1179-83.
9. Volc-Platzer B, Hönigsmann H, Hinterberger W, Wolff K. Photochemotherapy improves chronic cutaneous graft-versus-host disease. J Am Acad Dermatol 1990;23;220-8.
10. Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kahls P, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998;92:3098-104.
11. Grundmann-Kolmann M, Behrens S, Gruss C, Gottlöber P, Peter RU, Kerscher M. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000; 42:134-36.
12. Stander H, Schiller M, Schwarz T: UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 2002;46:799-800.
13. Krutmann J, Morita A. Mechanisms of ultraviolet (UV) B and UVA phototherapy. J Invest Dermatol Proc 1999;6:70-2.
14. Godar DE. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol 1999;112:3-12.
15. Herrmann G, Wlashek M, Bolsen K, Prenzel K, Goerz G, Scharfettner-Kochanek K. Photosensitization of uroporphyrin augments the ultraviolet Ainduced synthesis of matrix metalloproteinases in human dermal fibroblasts. J Invest Dermatol 1996;107:398-403.
16. Horn TD, Zahurak ML, Atkins D, Solomon AR, Vogelsang GB. Lichen planus-like histopathologic characteristics in the cutaneous graft-versus-host reaction. Arch Dermatol 1997; 133:961-5.
17. Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas ED and the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic bone marrow transplantation. N Engl J Med 1981;304:1529-33.
18. Spencer JM, Amonette R. Tanning beds and skin cancer: artificial sun + old sol=real risk. Clin Dermatol 1998;16:487-501.
19. Berg D, Otley CC: Skin cancer in organ transplant recipients: epidemiology, pathogenesis and management. J Am Acad Dermatol 2002;47:1-17.